BioCentury | Aug 5, 2019
Company News

Aug. 5 Company Quick Takes: Briefing docs for Descovy cast doubt on full PrEP approval; plus Alnylam, Provention and more

...repurposed to treat cancer. Financial terms are undisclosed. Neuropore in target discovery deal with BenevolentAI Neuropore Therapies Inc....
...emtricitabine/tenofovir alafenamide (Generic), F/TAF (Informal), Descovy (Other) givosiran (ALN-AS1) teplizumab (MGA031, PRV-031) Alnylam Pharmaceuticals Inc. BenevolentAI Cures Within Reach Gilead Sciences Inc. Neuropore Therapies Inc. Provention...
BioCentury | Jun 20, 2017
Distillery Therapeutics

Cancer

...AG have BIIB054 , a human mAb targeting α-synuclein, in Phase I to treat PD. Neuropore Therapies Inc....
BioCentury | Mar 28, 2016
Clinical News

UCB1332: Phase I data

...well tolerated. UCB has exclusive, worldwide rights to NPT200-11 from Neuropore under a 2015 deal. Neuropore Therapies Inc....
BioCentury | Jan 17, 2015
Company News

UCB licenses Neuropore's PD compound

Neuropore Therapies Inc., a subsidiary of Ever Neuro Pharma GmbH (Unterach, Austria), granted UCB Group (Euronext:UCB) an exclusive, worldwide license to preclinical Parkinson's disease candidate NPT200-11. The compound inhibits oligomerization of alpha synuclein ( SNCA ),...
Items per page:
1 - 4 of 4
BioCentury | Aug 5, 2019
Company News

Aug. 5 Company Quick Takes: Briefing docs for Descovy cast doubt on full PrEP approval; plus Alnylam, Provention and more

...repurposed to treat cancer. Financial terms are undisclosed. Neuropore in target discovery deal with BenevolentAI Neuropore Therapies Inc....
...emtricitabine/tenofovir alafenamide (Generic), F/TAF (Informal), Descovy (Other) givosiran (ALN-AS1) teplizumab (MGA031, PRV-031) Alnylam Pharmaceuticals Inc. BenevolentAI Cures Within Reach Gilead Sciences Inc. Neuropore Therapies Inc. Provention...
BioCentury | Jun 20, 2017
Distillery Therapeutics

Cancer

...AG have BIIB054 , a human mAb targeting α-synuclein, in Phase I to treat PD. Neuropore Therapies Inc....
BioCentury | Mar 28, 2016
Clinical News

UCB1332: Phase I data

...well tolerated. UCB has exclusive, worldwide rights to NPT200-11 from Neuropore under a 2015 deal. Neuropore Therapies Inc....
BioCentury | Jan 17, 2015
Company News

UCB licenses Neuropore's PD compound

Neuropore Therapies Inc., a subsidiary of Ever Neuro Pharma GmbH (Unterach, Austria), granted UCB Group (Euronext:UCB) an exclusive, worldwide license to preclinical Parkinson's disease candidate NPT200-11. The compound inhibits oligomerization of alpha synuclein ( SNCA ),...
Items per page:
1 - 4 of 4